Hello Dr. Bob and all,
Sorry it has taken me longer than promised to get back to the thread!
Thanks for the URL's and the info Dr. Bob :o)
As promised, here is the shareholders letter:
Dear Shareholders,
Please allow me a few moments of your time to update you on the activities, accomplishments and recent developments which your management team has undertaken during the last six months. First, let me ask your understanding in not releasing a "Shareholder letter" last quarter, as the last press releases demonstrate, we have been actively engaged in a variety of negotiations which required strict confidentiality. While we all appreciate the constant flow of information, I am sure you understand the absolute necessity of maintaining a tight level of confidentiality regarding our strategies, business development plans and eventual partnerships until we are certain that public disclosure will not compromise the Company's interests.
At this time, however, I would like to share with you the thoughts and strategic direction which went into the activites which have recently been disclosed. For your convenience, I have enclosed copies of these press releases for your reference. In addition, I encourage you to regularly review the company's SEC filings which may be accessed at either: "www.sec.gov.com"; or through the Company's website homepage: "www.MDI-P.com".
THE MDI MISSION STATEMENT
The management of Medical Discoveries Inc. is committed to transforming MDI into a revenue producing, "world class" Bio-Pharmaceutical Company. This means that while we continue in the development of our core compound, MDI-P, for eventual commercialization, we must, in the meantime, create more immediate revenue producing opportunities. We plan to achieve this objective by capitolizing on the ever-increasing business and market opportunities which our core electrolysis technology, patents, and research and development scientists have made available.
As a shareholder, it is important you realize that the activities we have undertaken, and those which we will continue to pursue, are part of a well-defined strategy to maximize the significant investment MDI has made to date in technology, patents, research, validation testing and employees. At the same time, however, we are continuing on a "regulatory approval timetable" with MDI-P targeted at HIV/AIDS (anti-viral), Candida Albicans (anti-fungal) and Vancomycin resistant strains of Enterococcus (anti-bacterial) therapeutic applications, and sterilization of medical products.
The decision to enter "consumer products" markets such as home water purification, wound repair and skin care, and "cosmeceuticals" enables MDI to quickly obtain revenues and establish our technologies in a leadership position, with no diversion from our pursuit of FDA approval of MDI-P.
SUMMARY OF PRESS RELEASES
(Please refer to press releases already made available.)
SHAREHOLDER VALUE PROGRAM
We have established a Shareholder Value Program which provides you the opportunity to take advantage of special pricing for products from MDI HealthCare Systems and Regenere. The attached Shareholder Value Business Reply Card offers special introductory pricing to shareholders on both the Millenium Aqua series products, and Kelo-cote. We are pleased to be able to provide our shareholders an opportunity to personally enjoy the benefits of these truly unique products.
Thankyou for your continued loyalty and support of our company. Until our next communication, I remain
Very Truly Yours,
Lee F. Kulas
President and Chief Executive Officer
|
